|1.||Hypertension (High Blood Pressure)
|4.||Left Ventricular Dysfunction
|1.||Gheorghiade, Mihai: 208 articles (12/2015 - 01/2002)|
|2.||McMurray, John J V: 193 articles (12/2015 - 01/2002)|
|3.||van Veldhuisen, Dirk J: 189 articles (01/2016 - 03/2002)|
|4.||Swedberg, Karl: 170 articles (12/2015 - 04/2002)|
|5.||Anker, Stefan D: 168 articles (12/2015 - 01/2002)|
|6.||Fonarow, Gregg C: 167 articles (01/2016 - 01/2002)|
|7.||Cleland, John G F: 166 articles (10/2015 - 01/2002)|
|8.||O'Connor, Christopher M: 162 articles (01/2016 - 01/2002)|
|9.||Abraham, William T: 134 articles (01/2016 - 01/2002)|
|10.||Tang, W H Wilson: 134 articles (01/2016 - 01/2002)|
|1.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
11/01/2000 - "Although most primary care physicians stated they prescribe ACE inhibitors in heart failure, this was for only 47-62% of patients, and at doses below those identified as effective in trials. "
10/02/1990 - "An understanding of the renal effects of ACE inhibitors permits their safe and effective use in most patients with congestive heart failure."
02/01/2000 - "Although angiotensin-converting enzyme inhibitors are recommended as first line therapy in patients with chronic heart failure, the target doses proven to be effective in major morbidity and mortality trials (e.g. "
12/01/1997 - "Several studies document an underuse of angiotensin-converting enzyme inhibitors (ACEIs) in heart failure (HF) patients, despite their proven efficacy and good tolerability. "
12/01/2002 - "Given the dramatic decline in quality of life with heart failure, this end-point should be a much more important target for healthcare interventions, especially treatments such as ACE inhibitors and beta-blockers that are shown to improve quality of life."
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/01/2010 - "Pharmacological therapies like beta blockade and angiotensin converting enzyme inhibition have proven beneficial in early stages of heart failure with pathological remodeling. "
12/01/2002 - "This is important since interventions that have been shown to improve mortality in patients with heart failure such as angiotensin converting enzyme inhibitor and beta-blockers had a favorable impact on the LV remodeling process. "
03/28/2008 - "Angiotensin-converting enzyme inhibitor (ACEI) is beneficial in patients with congestive heart failure (CHF). "
01/01/2002 - "The overall high rates of adherence to angiotensin-converting enzyme inhibitor therapy observed among heart failure clinic patients is consistent with research that shows improved outcomes for patients managed in heart failure clinics. "
08/01/2000 - "Although inhibitors of angiotensin-converting enzyme (ACE) have improved the treatment of chronic heart failure (CHF), mortality related to this disorder remains unacceptably high. "
|3.||Brain Natriuretic Peptide (Natrecor)FDA Link
02/01/2003 - "The results of several recent clinical trials have shown that administration of nesiritide is safe and highly effective for the initial treatment of patients with acutely decompensated heart failure and can help physicians and nurses meet treatment goals for the management of patients with this serious condition."
11/01/2004 - "Nesiritide has proven to be an effective new treatment for patients with decompensated heart failure."
03/01/2004 - "Nesiritide is a newer neurohormonal agent with proven efficacy and safety for use in decompensated heart failure, but appropriate patient selection has been challenging for clinicians. "
03/01/2015 - "There was significant improvement in NYHA class (3.0 vs 2.1, P = .002; 13/17 improved); Minnesota Living with Heart Failure Questionnaire (42 ± 26 vs 27 ± 22, P = .026; 12/17 improved); peak maximum oxygen consumption (14.6 ± 3.3 vs 16.5 ± 3.9 mL/kg/min, P = .013; 10/15 improved); LVEF (25% ± 6% vs 37% ± 8%, P<.001; 14/16 improved); and LV end-systolic volume (174 ± 57 vs 137 ± 37 mL, P = .002; 11/16 improved) but not in N-terminal prohormone brain natriuretic peptide. "
01/01/2013 - "Although no significant correlation was observed between plasma brain natriuretic peptide (BNP) and plasma miR-210 levels in patients with NYHA II heart failure, patients with an improved BNP profile at the subsequent hospital visit were classified in a subgroup of patients with low plasma miR-210 levels. "
|4.||carvedilol (Coreg)FDA LinkGeneric
06/01/2002 - "This suggests that carvedilol therapy for patients with severe chronic heart failure is not only safe and effective but is highly cost effective in the Irish healthcare setting."
04/01/1996 - "The Australia and New Zealand carvedilol heart failure study is the largest completed study of beta-blocker treatment in patients with heart failure of ischaemic aetiology, including 415 patients randomized to carvedilol or placebo and indicating excellent tolerability of a titrated dose regimen and improved ventricular function after 6 months of treatment. "
03/01/2011 - "We hypothesized that carvedilol might be another safe treatment option in chronic AR, considering its combined β-blocking and α-blocking effects and proven efficacy in patients with established heart failure. "
10/16/2007 - "One drug, carvedilol, a nonsubtype-selective betaAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. "
09/01/2007 - "Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure."
03/01/2000 - "In addition to their clinical benefits, diuretics are the most cost-effective treatment of any single drug group currently available for the treatment of patients with congestive heart failure."
01/01/2014 - "Diuretics are clearly beneficial in the treatment of acute decompensated heart failure. "
01/01/2009 - "In conclusion, doubling the dose of diuretics in outpatients with symptomatic congestive heart failure caused a significant loss of weight and a significant improvement in symptoms and 6-minute walk distance but did not change LV systolic and diastolic function."
06/01/2002 - "Heart failure was treated successfully with digitalis and diuretics. "
01/01/2013 - "A large trial is ongoing to determine if a strategy of early UF, initiated before renal function is worsened by other therapies, is superior to IV diuretics in reducing 90-day heart-failure-related hospitalizations in patients with pulmonary and systemic congestion. "
|6.||Digoxin (Digitek)FDA LinkGeneric
03/09/2004 - "Digoxin, which is one of the most commonly prescribed drugs for the treatment of heart failure, is mainly eliminated from the circulation by the kidney. "
04/01/1989 - "Thus, digoxin therapy is associated with a significant improvement in exercise capacity in patients with chronic heart failure, most likely due to an improved matching of ventilation to perfusion."
04/01/2009 - "Digoxin is an important therapeutic agent for the treatment of congestive cardiac failure. "
11/15/2008 - "Previous trials have shown that digoxin was beneficial in patients with heart failure (HF). "
01/01/2009 - "Digoxin is an agent that is readily available, can be administered acutely and long-term, intravenously or orally, is safe and may be beneficial in both acute and chronic heart failure (HF). "
|7.||Captopril (Capoten)FDA LinkGeneric
08/01/1996 - "The use of captopril showed important improvement in exercise capacity in patients with heart failure. "
12/01/1985 - "In some of the patients with chronic heart failure, captopril (6.25 mg) induced a marked decrease of the arterial blood pressure. "
04/05/1993 - "Captopril greatly contributes to the successful therapy of the chronic severe heart failure."
03/01/1993 - "A short period of treatment with intravenous captopril may produce a rapid symptomatic improvement in patients with acute or severe heart failure. "
05/01/1992 - "This partial preservation of beta-adrenergic responsiveness was accompanied by a significant reduction in right ventricular weight and lung weight, suggesting that captopril also improved the signs of heart failure. "
|8.||Spironolactone (Aldactone)FDA LinkGeneric
01/01/2009 - "The Randomized Aldactone Evaluation Study showed that low-dose spironolactone treatment dramatically reduced mortality in patients with heart failure. "
04/01/2003 - "This economic evaluation suggests that the addition of spironolactone to standard therapy for patients with severe chronic heart failure is not only safe and effective, but is highly cost-effective in the Irish healthcare setting."
06/19/1990 - "Although many new drugs useful in the treatment of congestive heart failure have been introduced during the past 25 years, spironolactone continues to have an important role in the management of this condition. "
08/01/2004 - "Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF). "
08/01/2002 - "Although the additional therapies with beta-blockers and spironolactone have recently proved to be significantly beneficial for the treatment of advanced heart failure, in the end stages of this disease the prognosis remains quite poor. "
04/01/1983 - "In conclusion, the long-acting converting enzyme inhibitor, enalapril, was effective in patients with chronic congestive heart failure; however, additional studies will be necessary to further delineate the optimal dose range and identify those patients who are most likely to respond to the drug."
05/03/2001 - "Despite similar doses of drug in the two groups, enalapril therapy, as compared with placebo, was associated with a 44 percent reduction (95 percent confidence interval, 27 to 57 percent) in the risk of hospitalization for heart failure among the white patients (P<0.001) but with no significant reduction among black patients (P=0.74). "
12/01/1993 - "The effect of enalapril on mortality and hospitalization for heart failure was significantly greater for patients with the lowest ejection fraction. "
07/01/1991 - "The acute efficacy of rapid loading of oral long-acting enalapril in congestive heart failure remains to be established. "
07/11/1988 - "There was a significant improvement in New York Heart Association classification in the enalapril group, together with a reduction in heart size and a reduced requirement for other heart failure medication. "
08/01/2014 - "Marked improvement was achieved after administration of Tolvaptan for heart failure in the postoperative period. "
09/01/2010 - "However, tolvaptan has not proven to be beneficial for the long-term management of heart failure. "
02/01/2014 - "Slow up-titration of the tolvaptan improved the loop diuretic-resistant congestive cardiac failure without hypernatraemia, deterioration of vital signs, and significant complications. "
03/01/2010 - "In patients with congestive heart failure (CHF) and symptoms of volume overload, tolvaptan prompted rapid free water elimination and improved short-term signs and symptoms of HF, although no effect on long-term mortality or HF-related morbidity was observed. "
12/01/2008 - "Tolvaptan is also effective for treatment of congestive heart failure (CHF) exacerbation, but whether there are long standing beneficial effects on CHF is still controversial. "
|1.||Cardiac Resynchronization Therapy
07/01/2011 - "Cardiac resynchronization therapy (CRT) has dramatically improved the symptoms and prognosis of patients with heart failure in large randomized clinical trials. "
04/01/2014 - "Although cardiac resynchronization therapy (CRT) is effective in most patients with heart failure (HF) and ventricular dyssynchrony, a significant minority of patients (approximately 30%) are non-responders. "
07/01/2012 - "Some chronic heart failure (CHF) patients show remarkable improvement in left ventricular (LV) remodeling after cardiac resynchronization therapy (CRT), for unclear reasons. "
10/01/2009 - "To the best of our knowledge, this is the first report of improved sexual function in a patient with heart failure and ED following cardiac resynchronization therapy. "
12/01/2006 - "Cardiac resynchronization therapy may lead to remarkable improvement in clinical status in selected patients with heart failure. "
|2.||Heart Transplantation (Grafting, Heart)
03/01/2015 - "Heart transplantation has become the most effective treatment for end-stage heart failure. "
01/01/2015 - "Heart transplantation is considered the gold standard therapy for the advanced heart failure, but donor shortage, especially in pediatric patients, is the main limitation for this procedure, so most sick patients die while waiting for the procedure. "
01/01/2015 - "Heart transplantation has, over the years, become the best treatment choice for patients with end-stage heart failure. "
07/01/2014 - "Cardiac transplantation remains the gold standard for end stage heart failure however results of long-term mechanical circulatory support have dramatically improved over the last 10years. "
02/01/2014 - "A remarkable number of patients survived 20 years or greater after heart transplantation, confirming the procedure as the gold standard for end-stage heart failure. "
|3.||Transplantation (Transplant Recipients)
01/01/2007 - "The HeartMate VE LVAS dramatically improved the functional status and quality of life of these three patients with end-stage heart failure, and all were successfully bridged to transplantation after 659, 995, and 1055 days of support on the device. "
08/01/2010 - "Transplantation of pluripotent stem cells has proven beneficial in heart failure, yet the proteomic landscape underlying repair remains largely uncharacterized. "
11/01/2007 - "Left ventricular assist device (LVAD) implantation has proven effective as a bridge to transplantation in end-stage heart failure patients (ESHFPs), although survival during device support is critical. "
07/04/2006 - "Optimal medical therapy is superior to transplantation for the treatment of class I, II, and III heart failure: a decision analytic approach."
01/01/2002 - "By combining operative techniques with optimal medical management of heart failure, good outcome can avoid or postpone transplantation. "
|4.||Drug Therapy (Chemotherapy)
08/01/2005 - "Most of the major trials of pharmacotherapy for the management of chronic heart failure have failed to include significant numbers of African-American patients. "
01/01/2009 - "Principal innovations in the management of chronic heart failure are explained, including the most important features of new management models for patients with chronic heart failure and the main advances in drug therapy and in the use of and indications for cardiac devices in these patients. "
03/10/2007 - "When CSR persists despite optimal drug therapy for heart failure, non-invasive ventilation, particularly as adaptive servoventilation, and cardiac resynchronisation therapy are currently the most promising treatment options."
12/01/2001 - "There is convincing evidence in the literature that tailored drug therapy can be highly effective in preventing heart failure progression as well as in reducing total and sudden mortality. "
08/01/2013 - "There was a significant improvement of optimal pharmacotherapy for chronic heart failure in Taiwan. "
11/01/2015 - "With the insufficient number of cardiac donors, use of a left ventricular assist device for patients with end-stage cardiac failure who are awaiting transplant may be the best option."
11/01/2015 - "Heart transplant is the best treatment for end-stage heart failure. "
11/01/2013 - "Advanced heart failure (HF) is a debilitating condition for which heart transplant (HT) offers the best treatment option. "
03/01/2013 - "Continuous-flow left ventricular assist devices (cfLVADs) have been proven safe and effective for bridge-to-transplant and destination therapy (DT) in patients with advanced heart failure. "
08/01/2004 - "Heart transplants are a proven effective therapy for selected patients with end-stage congestive heart failure. "